Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Abgenix: Opening the spigot

Abgenix Inc. has been working under a self-imposed limit of six deals per year for its XenoMouse human antibody technology due to resource constraints. But the company says that the combination of large new collaborations and the acquisition of full rights to the mouse

Read the full 440 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers